Fabry Disease
Conditions
Brief summary
This is a 54-week Phase 4, open label, single arm study to evaluate the safety and the efficacy of Fabrazyme (agalsidase beta) as enzyme replacement therapy (ERT) in Chinese participants with Fabry Disease.
Detailed description
Study participation for each patient will be total of 54 weeks which will include 4 weeks of screening, 48 weeks of treatment period and 2 weeks of post study treatment observation
Interventions
DRUGAgalsidase beta
Powder for concentration into a solution Intravenous (IV) infusion
Sponsors
Genzyme, a Sanofi Company
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
8 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant must be 8 years of age or older, at the time of signing the informed consent * Participants naive to agalsidase beta and agalsidase alpha * Chinese participants diagnosed with Fabry disease and with documented plasma or leukocyte αGAL activity deficient below laboratory's reference range, and/or documented diagnosis by genotyping * Participants must have one or more symptoms and signs consistent with manifestations of Fabry disease (not limited to neuropathic pain, chronic kidney disease, hypertrophic cardiomyopathy, cardiac rhythm disturbances, cerebrovascular involvement, cornea verticillata, angiokeratoma, gastrointestinal symptoms, hypo- or anhydrosis) * A female participant is eligible to participate if she is not pregnant or breastfeeding and use an acceptable contraceptive method * Participants and/or participant's legal representative capable of giving signed informed consent.
Exclusion criteria
* The participant has undergone kidney transplantation. * The participant has a clinically significant organic disease (with the exception of symptoms relating to Fabry disease) in the opinion of the Investigator, would preclude participation in the trial. * Received an investigational drug, or device, other than Fabrazyme, within 30 days of anticipated IMPs administration or 5 half-lives of the previous investigational drug, whichever is longer. * The patient has current evidence of kidney failure or renal insufficiency, as defined by eGFR \<30 mL/min/1.73 m2. * Individuals who have life threatening hypersensitivity (anaphylactic reaction) to the active substance or any of the excipients included. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment-emergent adverse events (AEs) | Baseline to week 50 | Including TEAE, SAEs, and adverse events of special interest (AESIs) including infusion associated reactions (IARs) and change of clinical laboratory, vital signs and ECG |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The percent changes of plasma lyso-GL3 | from baseline to Week 6, Week 12, Week 24 and Week 48 | — |
| The absolute changes of plasma globotriaosylceramide (GL3) | from baseline to Week 6, Week 12, Week 24 and Week 48 | — |
| The percent changes of plasma GL3 | from baseline to Week 6, Week 12, Week 24 and Week 48 | — |
| The number of participants with abnormal plasma GL3 values per central lab reference range | at Week 6, Week 12, Week 24 and Week 48 | — |
| The absolute changes of plasma globotriaosylsphingosine (lyso-GL3) | from baseline to Week 6, Week 12, Week 24 and Week 48 | — |
| The change of Fabry disease symptoms | from baseline to Week 24 and Week 48 | The change of Fabry disease symptoms assessment (improved, worsen or same): angiokeratoma, sweating, chronic abdominal pain, level of activity, exercise tolerance and heat tolerance, headache, tinnitus |
| The absolute change of estimated glomerular filtration rate (eGFR) by chronic kidney disease epidemiology collaboration (CKD-EPI) for adult (≥18 years) | from baseline to Week 12, Week 24, Week 36 and Week 48 | — |
| The absolute change of estimated glomerular filtration rate (eGFR) by Schwartz for children (8 ≤age <18 years) | from baseline to Week 12, Week 24, Week 36 and Week 48 | — |
| The percentage of participants with abnormal plasma GL3 values per central lab reference range | at Week 6, Week 12, Week 24 and Week 48 | — |
Countries
China
Outcome results
None listed